NO20092473L - Kombinasjon - Google Patents

Kombinasjon

Info

Publication number
NO20092473L
NO20092473L NO20092473A NO20092473A NO20092473L NO 20092473 L NO20092473 L NO 20092473L NO 20092473 A NO20092473 A NO 20092473A NO 20092473 A NO20092473 A NO 20092473A NO 20092473 L NO20092473 L NO 20092473L
Authority
NO
Norway
Prior art keywords
combination
aml
mds
hdai
contributory
Prior art date
Application number
NO20092473A
Other languages
English (en)
Norwegian (no)
Inventor
Peter Wisdom Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39272127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092473(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20092473L publication Critical patent/NO20092473L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20092473A 2006-12-04 2009-06-30 Kombinasjon NO20092473L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86838806P 2006-12-04 2006-12-04
PCT/US2007/024712 WO2008070011A2 (en) 2006-12-04 2007-11-30 Combination of an hdac inhibitor and an antimetabolite

Publications (1)

Publication Number Publication Date
NO20092473L true NO20092473L (no) 2009-09-01

Family

ID=39272127

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092473A NO20092473L (no) 2006-12-04 2009-06-30 Kombinasjon

Country Status (25)

Country Link
US (1) US8093220B2 (pt)
EP (1) EP2099451B1 (pt)
JP (3) JP5784274B2 (pt)
KR (1) KR101475538B1 (pt)
CN (1) CN101553223A (pt)
AR (1) AR064072A1 (pt)
AU (1) AU2007328281B2 (pt)
BR (1) BRPI0719746A2 (pt)
CA (1) CA2670741C (pt)
CL (1) CL2007003467A1 (pt)
EC (1) ECSP099483A (pt)
ES (1) ES2569477T3 (pt)
GT (1) GT200900148A (pt)
IL (1) IL198638A (pt)
MA (1) MA30982B1 (pt)
MX (1) MX2009005946A (pt)
MY (1) MY148893A (pt)
NO (1) NO20092473L (pt)
PE (1) PE20081303A1 (pt)
PL (1) PL2099451T3 (pt)
RU (1) RU2469717C2 (pt)
TN (1) TN2009000213A1 (pt)
TW (1) TW200831075A (pt)
WO (1) WO2008070011A2 (pt)
ZA (1) ZA200903041B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019033B1 (ru) 2008-03-26 2013-12-30 Новартис Аг Ингибиторы дезацетилазы в, основанные на гидроксамате
EP2306996A1 (en) * 2008-07-18 2011-04-13 Novartis AG Use of hdac inhibitors for the treatment of hodgkin's disease
WO2010009285A1 (en) * 2008-07-18 2010-01-21 Novartis Ag Use of hdac inhibitors for the treatment of acute myeloid leukemia and/or myelodysplastic syndrome
US20110053925A1 (en) * 2009-08-28 2011-03-03 Novartis Ag Hydroxamate-Based Inhibitors of Deacetylases
CA2801891C (en) * 2010-06-07 2020-10-27 Abraxis Bioscience, Llc Combination therapy methods for treating proliferative diseases
CA2808908A1 (en) * 2010-09-01 2012-03-08 Novartis Ag Combination of hdac inhibitors with thrombocytopenia drugs
JP6320506B2 (ja) * 2013-03-12 2018-05-09 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
JP2016538310A (ja) * 2013-11-27 2016-12-08 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法
SG11201702119PA (en) 2014-09-17 2017-04-27 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
WO2004103358A2 (en) * 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents

Also Published As

Publication number Publication date
ECSP099483A (es) 2009-08-28
PE20081303A1 (es) 2008-10-28
KR20090087115A (ko) 2009-08-14
RU2469717C2 (ru) 2012-12-20
CA2670741C (en) 2016-04-12
WO2008070011A2 (en) 2008-06-12
ZA200903041B (en) 2010-03-31
AU2007328281A1 (en) 2008-06-12
MX2009005946A (es) 2009-06-17
EP2099451A2 (en) 2009-09-16
IL198638A (en) 2015-06-30
CA2670741A1 (en) 2008-06-12
US20100069318A1 (en) 2010-03-18
CL2007003467A1 (es) 2008-07-11
HK1132462A1 (zh) 2010-02-26
JP5784274B2 (ja) 2015-09-24
AU2007328281B2 (en) 2011-03-31
JP2010511702A (ja) 2010-04-15
MY148893A (en) 2013-06-14
JP2016006070A (ja) 2016-01-14
GT200900148A (es) 2011-08-02
TN2009000213A1 (en) 2010-10-18
IL198638A0 (en) 2010-02-17
ES2569477T3 (es) 2016-05-11
PL2099451T3 (pl) 2016-07-29
MA30982B1 (fr) 2009-12-01
WO2008070011A3 (en) 2008-07-24
US8093220B2 (en) 2012-01-10
AR064072A1 (es) 2009-03-11
RU2009125439A (ru) 2011-01-20
BRPI0719746A2 (pt) 2013-12-10
CN101553223A (zh) 2009-10-07
TW200831075A (en) 2008-08-01
JP2014097992A (ja) 2014-05-29
EP2099451B1 (en) 2016-02-10
KR101475538B1 (ko) 2014-12-22

Similar Documents

Publication Publication Date Title
TN2009000213A1 (en) Combination
UY32177A (es) Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
PH12018500768A1 (en) Purin derivatives for use in the treatment of fab-related diseases
WO2007058990A3 (en) Therapy using cytokine inhibitors
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
EA200901308A1 (ru) Ингибиторы белка, активирующего 5-липоксигеназу (flap)
BRPI0622054B8 (pt) composto e composição farmacêutica
BR112014011645A2 (pt) combinação de um inibidor da fosfoinositida 3-quinase e um modulador da quinase janus 2-transdutor de sinal e ativador da via de transcrição 5
EA201100266A1 (ru) Диокса-бицикло[3.2.1]октан-2,3,4-триольные производные
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
DOP2010000011A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
MY151159A (en) 5-lipoxygenase-activating protien (flap) inhibitors
MX2010002410A (es) Metodo para proveer los beneficios de energia, alivio del estres y mejora del estado de animo, que comprende administrar una composicion que comprende colecalciferol y un extracto de te.
EA200801164A3 (ru) Ингибиторы протеина, активирующего 5-липоксигеназу (flap)
UA101903C2 (ru) Лекарственное средство на основе дииндолилметана для лечения гиперпластических и воспалительных заболеваний
NO20074318L (no) Anvendelse av en fettsyresammensetning som inneholder DHA for fremstilling av et medisinsk produkt eller et naeringsmiddel for behandling av amyloidoserelaterte sykdommer
CO6640335A2 (es) Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application